Oakrum Pharma, LLC has entered an agreement with Biophore India Pharmaceuticals Pvt. Ltd. to develop and manufacture two prescription generic pharmaceuticals for commercialization in the U.S. under the Oakrum label.  It is anticipated that both products will be sold through the specialty distribution market channel. The products in the U.S. exceeded $150 million in sales 2018, according to Bloomberg data.  Marco Polizzi, chief executive officer of Oakrum, said, “The partnership with Bio...